Patient-derived primary prostate cancer epithelial cultures for studying prostate cancer cell evolution under hypoxia.

R Robert G. Bristow A Alex Suvac (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) J Jack Ashton (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) R Richard Rebello (University of Melbourne Centre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, Australia) S Stephen Lyons (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) S Shaun Scaramuzza (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) A Arfa Mehmood (Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom) C Claire Alexandra Hart (Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom) M Martin Swinton (Manchester Cancer Research Centre, Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom) L Lucy Barton (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) G Giselle Edge (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) P Pedro Oliveira E Emma Woodward (Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom) N Noel W. Clarke (Manchester Cancer Research Centre, Christie and Salford Royal NHS Foundation Trusts, University of Manchester, Manchester, United Kingdom) A Ashwin Sachdeva (Manchester Cancer Research Centre, Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom) D Diego Sanchez Martinez (CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom) M Maria Jakobsdottir (Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom) D David Wedge (Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom)

Abstract

397 Background: Genetic instability is a hallmark of cancer and a driving force of tumourigenesis. An emerging concept is that hypoxia can potentiate genetic instability and tumour evolution leading to a poor clinical prognosis in localised prostate cancer. Mechanistic studies that explicitly test the ability for hypoxia to drive an increased DNA mutation burden and subsequent chromosomal instability(CIN) are lacking in sporadic and hereditary prostate cancer. We hypothesised that constant hypoxia selection pressure would increase clonal and sub-clonal selection for mutator phenotypes and CIN, beyond that achieved by aberrant cancer driver gene expression alone. Methods: We created isogenic single-hit and multi-hit prostate cell models for TP53, ATM, BRCA2 and RB loss and/or c-MYC overexpression using human telomerase ( hTERT )-immortalized prostate epithelial cell (PrEC) cultures. PrEC cultures were derived from morphologically-normal areas of radical prostatectectomy specimens. Isogenic cells were grown ex vivo under oxia (21% O 2 ), acute on chronic hypoxia (72h x 1% O 2 ) or constant long term, hypoxia exposure (20 generations x constant 1% O 2 ). Resulting DNA mutation burden and chromosomal instability were assayed using a combination of whole genome sequencing, RNAseq and immunofluorescent assessment of mitotic aberrations (antibodies against centrin-1, H3 phospho-serine10 and DAPI-DNA counterstain). Results: Under oxia, de novo percent genome alteration and micronuclei frequency was highest in the combined c-MYC/TP53 -/- clones compared to single gene c-MYC, BRCA2 -/- , ATM -/- or TP53 -/- clones. When growing the cells under acute on chronic hypoxic conditions (72 h, 1% O 2 ), there was an increase in micronuclei and centrosome aberrations across all genetic clone sub-types, with the highest incidence in c-MYC/TP53 -/- clones. Continued passaging of these cells led to increasing aneuploidy over time. Our CIN results were even more striking when using the PrEC cells with inactivated TP53 and RB (due to SV40 large T antigen transduction) following 20 generations of constant hypoxia. The observed increased percent genome alteration (45% increasing to 84%) was associated with increased micronuclei, PGCCs, erroneous anaphases and whole-genome duplication. In situ validation of these in vitro mechanistic studies is underway using spatial transcriptomic and whole genome profiling of 30 primary high-risk sporadic and hereditary prostatectomy specimens stained for hypoxic biomarkers (HYPROGEN trial: NCT05702619). Conclusions: Our results suggest that hypoxia augments genetic instability and CIN in cells secondary to cancer driver gene aberrations giving rise to clonal populations with selective advantage. These findings support the testing of therapeutic strategies that address both hypoxia and cancer driver mutations as a means to improve outcomes.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 397-397
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

R

Robert G. Bristow

A

Alex Suvac

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

J

Jack Ashton

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

R

Richard Rebello

University of Melbourne Centre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, Australia

S

Stephen Lyons

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

S

Shaun Scaramuzza

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

A

Arfa Mehmood

Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom

C

Claire Alexandra Hart

Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom

M

Martin Swinton

Manchester Cancer Research Centre, Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

L

Lucy Barton

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

G

Giselle Edge

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

P

Pedro Oliveira

E

Emma Woodward

Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

N

Noel W. Clarke

Manchester Cancer Research Centre, Christie and Salford Royal NHS Foundation Trusts, University of Manchester, Manchester, United Kingdom

A

Ashwin Sachdeva

Manchester Cancer Research Centre, Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

D

Diego Sanchez Martinez

CRUK Manchester Institute and University of Manchester, Manchester, United Kingdom

M

Maria Jakobsdottir

Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom

D

David Wedge

Manchester Cancer Research Centre and University of Manchester, Manchester, United Kingdom